Acute Anterior Uveitis Emerges as a Strong Signal in At-Risk Families
In families affected by ankylosing spondylitis, the search for earlier recognition of axial spondyloarthritis often begins long before imaging becomes definitive or inflammatory back pain is labeled as rheumatic disease. This 35-year family study followed first-degree relatives of probands with ankylosing spondylitis and asked which clinical features could actually separate relatives who later developed axSpA from those who did not. The answer was not subtle: acute anterior uveitis carried a markedly higher likelihood of axSpA in this high-risk population.
Among relatives who developed axSpA, AAU occurred in 13 of 34 participants, or 38.2%, compared with 29 of 251 relatives without axSpA, or 11.6%. The association was strong, with a p value of 0.00004 and an odds ratio of 4.74, with a 95% confidence interval from 2.15 to 10.47. In practical terms, eye inflammation in a genetically loaded family should not be treated as an isolated ophthalmic event. It is a clinical cue to look for spinal disease, sacroiliac inflammation, and the broader spondyloarthritis phenotype.
What the 35-Year Follow-Up Showed About Inherited Risk
The cohort began in 1985, when 363 ankylosing spondylitis probands and 806 first-degree relatives underwent rheumatologic examination, questionnaires, blood sampling for HLA typing, and radiography of the sacroiliac joints. Decades later, follow-up in 2018-2019 captured 125 patients and 360 first-degree relatives who completed a postal questionnaire focused on axSpA features. Relatives were also asked whether, after 1985, Swiss rheumatologists had diagnosed them with axSpA.
The long follow-up window is clinically meaningful because axSpA does not behave like a disorder that declares itself cleanly in a single visit. Symptoms can unfold slowly, and diagnostic labels often lag behind the first inflammatory clues. A family study spanning 35 years is unusually suited to this question because it tracks the interval between early symptoms and later clinical recognition, not just the snapshot of a single clinic encounter.
HLA-B27 status remained important, but the study’s most useful message was more specific: among HLA-B27-positive first-degree relatives, axSpA occurred in roughly one quarter of participants, at 25.4% to 26.3%, and this was independent of whether the proband had radiographic sacroiliitis. In other words, the genetic marker identified a vulnerable group, but the structural severity seen in the affected family member did not further refine the relatives’ risk in this dataset. Family history alone did not fully explain who would cross the line into clinically recognized disease.
Baseline Inflammatory Back Pain Was Not Enough on Its Own
Chronic inflammatory back pain is often treated as the bedside clue most likely to trigger suspicion for axSpA, yet this study did not support it as a stand-alone predictor of later disease among first-degree relatives when assessed at baseline. The finding is important because it reflects the limits of symptom-based screening when applied years before diagnosis, especially in a family already enriched for spondyloarthritis risk.
Symptoms evolve. A single historical questionnaire, even in a high-risk family, may miss the eventual pattern that becomes recognizable only later, once pain localizes differently or extra-spinal features appear. In this cohort, the more discriminating signal emerged when symptom domains were combined rather than treated as isolated items.
The combined presence of chronic inflammatory back pain and pain or discomfort in the thoracic spine and anterior chest wall, assessed at follow-up in 2018-2019, yielded 83.1% sensitivity and 87.2% specificity for current axSpA. This three-question approach is clinically attractive because it compresses complex axial disease behavior into a brief screen that can be used in families where suspicion should already be elevated.
Thoracic Spine and Chest Wall Pain Add Diagnostic Weight
Thoracic spine pain and anterior chest wall discomfort fit the pathophysiology of axial spondyloarthritis better than ordinary mechanical pain does. Inflammatory involvement of entheses and costosternal or costovertebral structures can produce symptoms outside the lower back, and those locations may be particularly informative when they occur alongside inflammatory back pain. The study’s performance characteristics suggest that symptom geography matters, not just symptom presence.
A sensitivity of 83.1% means the three-question tool captured most current axSpA cases in this family cohort. A specificity of 87.2% means it also avoided excessive false positives among relatives without disease. For clinicians working in familial settings, this combination matters because overly broad screening can flood referral pathways, while overly narrow screening delays diagnosis until structural damage or extra-articular disease becomes harder to reverse.
How the Findings Should Change Screening in Relatives
The most actionable implication is straightforward: acute anterior uveitis in a first-degree relative of an ankylosing spondylitis proband should trigger evaluation for axSpA. Ophthalmology and rheumatology often encounter the same patient through different doors, and this study argues for a lower threshold to connect those encounters when family history is already present.
The second implication is more nuanced but still practical. A brief symptom triad, built around chronic inflammatory back pain plus thoracic spine pain and anterior chest wall discomfort, may strengthen clinical suspicion when the diagnosis has not yet been made. This is not a replacement for imaging or specialist assessment. It is a structured way to identify the relatives most likely to warrant those next steps.
The cohort also illustrates why proband imaging severity is not enough to triage family members. Radiographic sacroiliitis in the affected proband did not alter the occurrence of axSpA among HLA-B27-positive first-degree relatives. Family counseling therefore cannot rely solely on the index patient’s x-ray phenotype to estimate who in the family is already moving toward disease.
A Family-Based Strategy for Earlier Recognition
This study adds a valuable layer to axSpA risk assessment in hereditary clusters. HLA-B27 identifies susceptibility, AAU points to occult axial disease, and a compact symptom set can sharpen suspicion when back pain alone is too nonspecific. The result is a more disciplined screening strategy for families already known to carry elevated risk.
The design also carries the usual constraints of long-term follow-up. Not every original participant remained available decades later, and current disease status depended in part on questionnaire-based recall and prior clinical diagnosis. Even so, the central signals were strong enough to support a focused message: in first-degree relatives of ankylosing spondylitis probands, eye inflammation and a specific pattern of axial symptoms deserve active attention, because both may mark disease that has been present longer than the chart suggests.